SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001544784-24-000056
Filing Date
2024-05-09
Accepted
2024-05-09 08:06:03
Documents
57
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ewtx-20240331x10q.htm   iXBRL 10-Q 1704059
2 EX-10.1 ewtx-20240331xex10d1.htm EX-10.1 43513
3 EX-31.1 ewtx-20240331xex31d1.htm EX-31.1 19400
4 EX-31.2 ewtx-20240331xex31d2.htm EX-31.2 19213
5 EX-32.1 ewtx-20240331xex32d1.htm EX-32.1 7531
6 EX-32.2 ewtx-20240331xex32d2.htm EX-32.2 7608
  Complete submission text file 0001544784-24-000056.txt   5660596

Data Files

Seq Description Document Type Size
7 EX-101.SCH ewtx-20240331.xsd EX-101.SCH 30495
8 EX-101.CAL ewtx-20240331_cal.xml EX-101.CAL 36242
9 EX-101.DEF ewtx-20240331_def.xml EX-101.DEF 118865
10 EX-101.LAB ewtx-20240331_lab.xml EX-101.LAB 304762
11 EX-101.PRE ewtx-20240331_pre.xml EX-101.PRE 221006
61 EXTRACTED XBRL INSTANCE DOCUMENT ewtx-20240331x10q_htm.xml XML 785242
Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

IRS No.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40236 | Film No.: 24928695
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)